Cited In for PMID: 33322337

Year	Number of Results
2020	1
2021	3
2022	4
2023	7
2024	2

1

Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines.

Fuentes-Baile M, Ventero MP, Encinar JA, García-Morales P, Poveda-Deltell M, Pérez-Valenciano E, Barberá VM, Gallego-Plazas J, Rodríguez-Lescure Á, Martín-Nieto J, Saceda M. Fuentes-Baile M, et al. Cancers (Basel). 2020 Dec 11;12(12):3717. doi: 10.3390/cancers12123717. Cancers (Basel). 2020. PMID: 33322337 Free PMC article.

2

Role of Insulin-like Growth Factor-1 Receptor in Tobacco Smoking-Associated Lung Cancer Development.

Shahid A, Santos SG, Lin C, Huang Y. Shahid A, et al. Biomedicines. 2024 Mar 2;12(3):563. doi: 10.3390/biomedicines12030563. Biomedicines. 2024. PMID: 38540176 Free PMC article. Review.

3

Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment.

Frumento D, Grossi G, Falesiedi M, Musumeci F, Carbone A, Schenone S. Frumento D, et al. Int J Mol Sci. 2024 Jan 23;25(3):1398. doi: 10.3390/ijms25031398. Int J Mol Sci. 2024. PMID: 38338677 Free PMC article. Review.

4

Identification of a Novel CD8⁺ T cell exhaustion-related gene signature for predicting survival in hepatocellular carcinoma.

Liu K, Liu J, Zhang X, Liu D, Yao W, Bu Y, Chen B. Liu K, et al. BMC Cancer. 2023 Dec 4;23(1):1185. doi: 10.1186/s12885-023-11648-x. BMC Cancer. 2023. PMID: 38049741 Free PMC article.

5

Applying a Gene Reversal Rate Computational Methodology to Identify Drugs for a Rare Cancer: Inflammatory Breast Cancer.

Ji X, Williams KP, Zheng W. Ji X, et al. Cancer Inform. 2023 Oct 14;22:11769351231202588. doi: 10.1177/11769351231202588. eCollection 2023. Cancer Inform. 2023. PMID: 37846218 Free PMC article.

6

Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase.

Zhang C, Zhao X, Wang Z, Gong T, Zhao H, Zhang D, Niu Y, Li X, Zhao X, Li G, Dong X, Zhang L, Liu C, Xu J, Yu B. Zhang C, et al. Invest New Drugs. 2023 Jun;41(3):438-452. doi: 10.1007/s10637-023-01360-9. Epub 2023 Apr 25. Invest New Drugs. 2023. PMID: 37097369

7

Drugging IGF-1R in cancer: New insights and emerging opportunities.

Wang P, Mak VC, Cheung LW. Wang P, et al. Genes Dis. 2022 Mar 23;10(1):199-211. doi: 10.1016/j.gendis.2022.03.002. eCollection 2023 Jan. Genes Dis. 2022. PMID: 37013053 Free PMC article. Review.

8

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.

Roche S, Gaule P, Winrow D, Mukherjee N, O'Neill F, Conlon NT, Meiller J, Collins DM, Canonici A, Fawsi MI, Estepa-Fernández A, Madden SF, Crown J, O'Donovan N, Eustace AJ. Roche S, et al. PLoS One. 2023 Mar 15;18(3):e0282512. doi: 10.1371/journal.pone.0282512. eCollection 2023. PLoS One. 2023. PMID: 36920947 Free PMC article.

9

Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target.

Liu G, Zhu M, Zhang M, Pan F. Liu G, et al. Cancers (Basel). 2023 Feb 17;15(4):1287. doi: 10.3390/cancers15041287. Cancers (Basel). 2023. PMID: 36831629 Free PMC article. Review.

10

Obesity and endocrine-related cancer: The important role of IGF-1.

Zhong W, Wang X, Wang Y, Sun G, Zhang J, Li Z. Zhong W, et al. Front Endocrinol (Lausanne). 2023 Jan 23;14:1093257. doi: 10.3389/fendo.2023.1093257. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36755926 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

16 results

Results by year